Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could changing carbs and adding fiber improve blood sugar in type 1 diabetes?

NCT ID NCT07673523

Disease control Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores how different amounts of carbohydrates and a fiber supplement called inulin-FOS affect blood sugar control in adults with type 1 diabetes. Participants will try three two-week diets: one with 30% carbs, one with 50-55% carbs, and one with 50-55% carbs plus inulin-FOS. Blood sugar is tracked continuously, and the goal is to find which approach works best for managing glucose levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inulin and fructooligosaccharide (FOS) dietary supplement
What this could lead to
If successful, this could help identify an optimal diet plan for better blood sugar management in type 1 diabetes.
What could go wrong
This is a small, short-term study with only 20 participants, so results may not apply to everyone. Dietary changes can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients aged 18-65 years diagnosed with Type 1 diabetes and currently using a Continuous Glucose Monitoring device Exclusion Criteria: * Individuals with type 2 diabetes * Individuals with gestational diabetes * Breastfeeding individuals * Individuals with celiac disease * Individuals with gastroparesis * Renal insufficiency (tGFR ≤ 60 ml/min/1.73 m2) * Diagnosed liver failure * Immunodeficiency * Individuals with malignancy * Using nutritional supplements that may affect metabolic parameters

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes mellitus

Contacts and locations

Locations

  • Hacettepe University

    Ankara, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.